Oramed Reports Strong Q1 Profitability Driven by Investment Gains and Strategic Shift to MedTech Operator Model

summarizeSummary

Oramed Pharmaceuticals reported a strong Q1 2026 net income of $38.31 million, a significant reversal from a prior-year loss, driven by revaluation gains on its strategic investments and the successful execution of its new medical technology operator model.

check_boxKey Events

• Return to Profitability

  The company reported a net income of $38.31 million for Q1 2026, a significant improvement from a net loss of $7.64 million in Q1 2025. Diluted EPS was $0.91, up from $(0.19).

• Strategic Shift to MedTech Operator Model

  Oramed has completed its strategic pivot to acquire controlling interests in medical technology businesses and actively manage their direction, moving away from its prior biotech R&D focus. This shift was previously announced in the 10-K on March 26, 2026.

• Substantial Investment Gains

  Financial income, net, surged to $44.85 million in Q1 2026 from a $2.56 million loss in Q1 2025, primarily due to a $36.43 million unrealized gain on its Alpha Tau investment and revaluation gains on Scilex and Hapisga investments.

• Lifeward Transaction Completed

  The disposition of the POD™ technology platform to Lifeward Ltd. closed on March 25, 2026, resulting in a $5.82 million gain on sale of IP and receipt of Lifeward shares, pre-funded warrants, share purchase warrants, and a $9 million senior secured convertible note.

auto_awesomeAnalysis

Oramed Pharmaceuticals has successfully transitioned from a biotech R&D company to a strategic operator of medical technology businesses, as evidenced by its first-quarter 2026 results. The company reported a significant net income of $38.31 million, a substantial turnaround from a $7.64 million net loss in the prior year, primarily driven by revaluation gains on its investment portfolio. Key drivers include a $36.43 million unrealized gain on its Alpha Tau investment and gains from the disposition of its POD™ technology platform to Lifeward. While cash and cash equivalents decreased significantly during the quarter, the company maintains it has sufficient liquidity for at least the next 12 months, supported by its growing investment portfolio and ongoing strategic transactions.